KIF5B

Summary

KIF5B (kinesin family member 5B, HGNC:6324) is a protein-coding gene on chromosome 10p11.22, encoding Kinesin-1 heavy chain (P33176). Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes.

Enables identical protein binding activity; microtubule binding activity; and microtubule motor activity. Involved in several processes, including natural killer cell mediated cytotoxicity; positive regulation of protein localization to plasma membrane; and vesicle transport along microtubule. Located in several cellular components, including centriolar satellite; cytosol; and nuclear membrane.

Source: NCBI Gene 3799 — RefSeq curated summary.

At a glance

• Gene–disease (curated): skeletal dysplasia (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 9
• Clinical variants (ClinVar): 135 total — 2 pathogenic, 3 likely-pathogenic
• Phenotypes (HPO): 2
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• MANE Select transcript: NM_004521

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6324
Approved symbol	KIF5B
Name	kinesin family member 5B
Location	10p11.22
Locus type	gene with protein product
Status	Approved
Aliases	KNS, uKHC
Ensembl gene	ENSG00000170759
Ensembl biotype	protein_coding
OMIM	602809
Entrez	3799

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000302418, ENST00000493889, ENST00000861448, ENST00000861449, ENST00000948543, ENST00000948544

RefSeq mRNA: 1 — MANE Select: NM_004521 NM_004521

CCDS: CCDS7171

Canonical transcript exons

ENST00000302418 — 26 exons

Exon	Start	End
ENSE00001135810	32015509	32015659
ENSE00001163712	32017143	32017359
ENSE00001163722	32018316	32018387
ENSE00001163747	32022140	32022257
ENSE00001163755	32022848	32023036
ENSE00001163760	32028428	32028571
ENSE00001163763	32031073	32031279
ENSE00001163772	32033845	32034038
ENSE00001163777	32034690	32034838
ENSE00001163782	32035522	32035667
ENSE00001163795	32037254	32037378
ENSE00001163802	32037520	32037607
ENSE00001163809	32038163	32038218
ENSE00001163815	32038778	32038826
ENSE00001163819	32039327	32039431
ENSE00001163823	32040384	32040457
ENSE00001163825	32048464	32048551
ENSE00001376582	32021226	32021287
ENSE00001387593	32021022	32021131
ENSE00001551533	32055848	32056425
ENSE00001799163	32035890	32035994
ENSE00001872441	32009015	32011516
ENSE00002512595	32032706	32032774
ENSE00003508460	32018052	32018156
ENSE00003543329	32018502	32018562
ENSE00003621273	32019858	32019959

Expression profiles

Bgee: expression breadth ubiquitous, 303 present calls, max score 99.63.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 79.0836 / max 832.9894, expressed in 1823 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
108992	78.4676	1823
108991	0.6161	225

Top tissues by expression

303 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cauda epididymis	UBERON:0004360	99.63	gold quality
caput epididymis	UBERON:0004358	99.49	gold quality
cranial nerve II	UBERON:0000941	99.44	gold quality
corpus epididymis	UBERON:0004359	99.41	gold quality
mucosa of paranasal sinus	UBERON:0005030	99.40	gold quality
inferior vagus X ganglion	UBERON:0005363	99.37	gold quality
visceral pleura	UBERON:0002401	99.30	gold quality
lower lobe of lung	UBERON:0008949	99.29	gold quality
medial globus pallidus	UBERON:0002477	99.23	gold quality
globus pallidus	UBERON:0001875	99.19	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.13	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.06	gold quality
superficial temporal artery	UBERON:0001614	99.04	gold quality
subthalamic nucleus	UBERON:0001906	99.04	gold quality
medulla oblongata	UBERON:0001896	98.94	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	98.87	gold quality
bronchial epithelial cell	CL:0002328	98.86	gold quality
heart right ventricle	UBERON:0002080	98.85	gold quality
superior vestibular nucleus	UBERON:0007227	98.84	gold quality
saphenous vein	UBERON:0007318	98.84	gold quality
biceps brachii	UBERON:0001507	98.83	gold quality
lateral globus pallidus	UBERON:0002476	98.79	gold quality
choroid plexus epithelium	UBERON:0003911	98.79	gold quality
pylorus	UBERON:0001166	98.75	gold quality
parietal pleura	UBERON:0002400	98.73	gold quality
colonic mucosa	UBERON:0000317	98.70	gold quality
jejunal mucosa	UBERON:0000399	98.70	gold quality
gluteal muscle	UBERON:0002000	98.68	gold quality
germinal epithelium of ovary	UBERON:0001304	98.67	gold quality
pons	UBERON:0000988	98.66	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	7.02
E-MTAB-6379	no	2683.11
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NEUROD6

miRNA regulators (miRDB)

227 targeting KIF5B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593

Literature-anchored findings (GeneRIF, showing 40)

• links neurofibromin and merlin in a common cellular pathway of neurofibromatosis (PMID:12191989)
• With residues 814-963 of human ubiquitous kinesin heavy chain (uKHC) used as bait, a synaptosome-associated protein of 25 kDa (SNAP25) has been identified as a kinesin-binding protein in a human brain cDNA library. (PMID:12475239)
• Results identify the ribosome receptor, p180, as a binding partner of the kinesin heavy chain isoform KIF5B. (PMID:15184079)
• CRMP-2 transports the Sra-1/WAVE1 complex to axons in a kinesin-1-dependent manner and thereby regulates axon outgrowth and formation (PMID:16260607)
• Demonstrates the utility of screening for PDGFRA kinase domain overexpression in patients with IHES and has identified KIF5B as a third PDGFRA fusion partner in chronic myeloproliferative disorders. (PMID:16498388)
• kinesin-1, but not kinesin-2, contributes to the specific cytoplasmic distribution of three of the four steps of VV morphogenesis tested. (PMID:17394562)
• binding of the kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria localization and function (PMID:17887960)
• We demonstrate that KIF5B mediates post-Golgi transport of an apical protein in epithelial cells, but only after polarity has developed. (PMID:17925227)
• Data suggest that the promotion of lamellipodia formation by HGF in MDA-MB-231 cells is Rac1-dependent and requires KIF5B-mediated transport of WAVE2 and IQGAP1 to the cell periphery along microtubules. (PMID:18514191)
• The interaction of the Switch I region of the kinesin-1 head with the tail is strikingly similar to the interactions of small GTPases with their regulators, indicating that other kinesin motors may share similar regulatory mechanisms. (PMID:18579780)
• data implicate kinesin-1 in the spatial organization of the ER/Golgi interface as well as in traffic outside the ER (PMID:18817524)
• training-induced changes in submaximal exercise stroke volume may be due to mitochondrial function and variation in KIF5B expression as determined by functional SNPs in its promoter. (PMID:18984674)
• KIF5B is a cancer relevant lysosomal motor protein with additional functions in autophagosome formation (PMID:19242560)
• RANBP2 is the first native and positive allosteric activator known to jump-start and boost directly the activity of KIF5B. (PMID:19305391)
• the interaction between the kinesin-1 head and its regulatory tail domain (PMID:19348763)
• role of the kinesin I isoform Kif5b in the trafficking of a cardiac voltage-gated potassium channel, Kv1.5 in Kv1.5-expressing HEK293 cells and H9c2 cardiomyoblasts (PMID:19675065)
• Na,K-ATPase traffic toward the plasma membrane in alveolar epithelial cells is driven by kinesin-1, where KLC2 is the isoform regulating this process. (PMID:19773350)
• This indicates that kinesin-1 facilitates the transport of SNAP-25 containing vesicles as a prerequisite to SNAP-25 driven membrane fusion events. (PMID:19913510)
• a kinesin-1 tail fragment associates with microtubules with submicromolar affinity and binding is largely electrostatic (PMID:20071331)
• The discovery of the novel KIF5B-ALK variant further consolidated the role of aberrant anaplastic lymphoma kinase signaling in lung carcinogenesis. (PMID:21656749)
• The conventional kinesin-microtubule binding free energy is dominated by van der Waals interactions and electrostatic interactions. (PMID:21910419)
• findings show a bipartite tryptophan-based motif in vaccinia virus A36 is required for kinesin-1-dependent transport of the virus; bioinformatic analysis reveals that related bipartite tryptophan-based motifs are present in over 450 human proteins (PMID:21915095)
• Kinesin-1-mediated capsid disassembly and disruption of the nuclear pore complex promote virus infection. (PMID:21925109)
• Arl8 and SKIP are required for lysosomes to distribute away from the microtubule-organizing center. We identify two kinesin light chain binding motifs in SKIP that are required for lysosomes to accumulate kinesin-1 and redistribute to the cell periphery. (PMID:22172677)
• Data indicate that mutant KIF5B kinesin-1 binds ATP similarly in the presence of either metal ion, but its ATP hydrolysis activity is greatly diminished in the presence of Mg(2+). (PMID:22198464)
• Expression of exogenous KIF5B-RET, induced morphological transformation and anchorage-independent growth of NIH3T3 fibroblasts (PMID:22327624)
• Nesca directly binds KIF5B, kinesin light-chain and syntaxin-1 (PMID:22404429)
• Study found the secretion of calu-1/2-EGFP required microtubule integrity, and that calu-1/2-EGFP-containing vesicles were transported by the motor proteins Kif5b and cytoplasmic dynein. (PMID:22514732)
• Patients without KIF5B-RET fusions had a better prognosis than those with KIF5B-RET fusions (median survival, 52.6 months vs 21.0 months). (PMID:23378251)
• Anti-oncogenic miR-203 had a pivotal role in melanoma through reducing melanosome transport and promoting melanogenesis by targeting kif5b and through negative regulation of the CREB1/MITF/Rab27a pathway. (PMID:23884313)
• when cargo is transported by both dynein and phosphorylated kinesin, a common occurrence in the cell, there may be a bias that favors motion toward the minus-end of microtubules. (PMID:24072715)
• Kinesin-1 transports c-MYC for proteasomal degradation in the cytoplasm. (PMID:24821626)
• Our data suggest that KIF5B-RET promotes the cell growth and tumorigenicity of non-small cell lung cancers through multilevel activation of STAT3 signaling, providing possible strategies for the treatment of KIF5B-RET positive lung cancers. (PMID:25047660)
• Authors find that pharmacological or small interfering RNA (siRNA)-mediated inhibition of cytoplasmic dynein or the kinesin 1 heavy chain KIF5B delays HIV-1 uncoating. (PMID:25231297)
• Kinesin-14 blocks microtubule nucleation in yeast and reveal that this inhibition is countered by the kinesin-5 protein, Cut7.[Cut7, Pkl1] (PMID:25348260)
• A novel role of KIF5B was shown in the spatial regulation of Cdo-BNIP-2-p38MAPK signaling and discloses a previously unappreciated linkage between the intracellular transporting system and myogenesis regulation. (PMID:25378581)
• compared to those of brain, on MCF7 microtubules, kinesin-1’s processivity is significantly reduced although its velocity is only slightly altered (PMID:25450690)
• nesprin-dependent recruitment of kinesin-1 to the nuclear envelope through the interaction of a conserved LEWD motif with kinesin light chain might be a general mechanism for cell-type-specific nuclear positioning during development. (PMID:25516977)
• This study has provided a comprehensive structural and dynamic picture of kinesin’s major ATPase states. (PMID:25537000)
• Myo1c significantly increases the frequency of kinesin-1-driven microtubule-based runs that begin at actin/microtubule intersections. The actin-binding protein tropomyosin 2 abolishes Myo1c-specific effects on both run initiation and run termination. (PMID:25660542)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	kif5ba	ENSDARG00000074131
danio_rerio	KIF5B	ENSDARG00000103394
mus_musculus	Kif5b	ENSMUSG00000006740
rattus_norvegicus	Kif5b	ENSRNOG00000017466
drosophila_melanogaster	Khc	FBGN0001308

Paralogs (41): KIF1B (ENSG00000054523), KIF26A (ENSG00000066735), KIF2A (ENSG00000068796), KIF22 (ENSG00000079616), KIF3C (ENSG00000084731), KIF9 (ENSG00000088727), KIF16B (ENSG00000089177), KIF4A (ENSG00000090889), KIF3B (ENSG00000101350), KIF20A (ENSG00000112984), KIF21B (ENSG00000116852), KIF17 (ENSG00000117245), KIF14 (ENSG00000118193), KIF18A (ENSG00000121621), KIF25 (ENSG00000125337), KIF1C (ENSG00000129250), KIF1A (ENSG00000130294), KIF3A (ENSG00000131437), KIF12 (ENSG00000136883), KIF13A (ENSG00000137177), KIF23 (ENSG00000137807), KIF11 (ENSG00000138160), CENPE (ENSG00000138778), KIF21A (ENSG00000139116), KIFC3 (ENSG00000140859), KIF2B (ENSG00000141200), KIF2C (ENSG00000142945), KIF5A (ENSG00000155980), KIF26B (ENSG00000162849), KIF15 (ENSG00000163808), KIF6 (ENSG00000164627), KIF27 (ENSG00000165115), KIF7 (ENSG00000166813), KIFC2 (ENSG00000167702), KIF5C (ENSG00000168280), KIF18B (ENSG00000186185), KIF24 (ENSG00000186638), KIF19 (ENSG00000196169), KIF13B (ENSG00000197892), KIF4B (ENSG00000226650)

Protein

Protein identifiers

Kinesin-1 heavy chain — P33176 (reviewed: P33176)

Alternative names: Conventional kinesin heavy chain, Ubiquitous kinesin heavy chain

All UniProt accessions (2): P33176, V9HW29

UniProt curated annotations — full annotation on UniProt →

Function. Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner. Regulates centrosome and nuclear positioning during mitotic entry. During the G2 phase of the cell cycle in a BICD2-dependent manner, antagonizes dynein function and drives the separation of nuclei and centrosomes. Required for anterograde axonal transportation of MAPK8IP3/JIP3 which is essential for MAPK8IP3/JIP3 function in axon elongation. Through binding with PLEKHM2 and ARL8B, directs lysosome movement toward microtubule plus ends. Involved in NK cell-mediated cytotoxicity. Drives the polarization of cytolytic granules and microtubule-organizing centers (MTOCs) toward the immune synapse between effector NK lymphocytes and target cells.

Subunit / interactions. Oligomer composed of two heavy chains and two light chains. Interacts with GRIP1 and PPP1R42. Interacts with SYBU. Interacts with JAKMIP1. Interacts with PLEKHM2. Interacts with ECPAS. Interacts with ZFYVE27. Found in a complex with OGT, RHOT1, RHOT2 and TRAK1. Interacts with APP (via cytoplasmic domain).

Subcellular location. Cytoplasm. Cytoskeleton. Cytolytic granule membrane. Lysosome membrane.

Domain organisation. Composed of three structural domains: a large globular N-terminal domain which is responsible for the motor activity of kinesin (it hydrolyzes ATP and binds microtubule), a central alpha-helical coiled coil domain that mediates the heavy chain dimerization; and a small globular C-terminal domain which interacts with other proteins (such as the kinesin light chains), vesicles and membranous organelles.

Similarity. Belongs to the TRAFAC class myosin-kinesin ATPase superfamily. Kinesin family. Kinesin subfamily.

RefSeq proteins (1): NP_004512* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001752	Kinesin_motor_dom	Domain
IPR019821	Kinesin_motor_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR027640	Kinesin-like_fam	Family
IPR036961	Kinesin_motor_dom_sf	Homologous_superfamily
IPR059182	Khc_C	Domain

Pfam: PF00225

Enzyme classification (BRENDA):

• EC 5.6.1.3 — plus-end-directed kinesin ATPase (BRENDA: 34 organisms, 94 substrates, 257 inhibitors, 53 Km, 52 kcat entries)

Substrate kinetics (BRENDA)

5 substrates with measured Km, best-characterized 5. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	—	45
ALEXA FLUOR 647 ATP	0.032	1
METHYLANTHRANILOYL-ATP	0.0004	1
ADP	—	0
PHOSPHATE	—	0

UniProt features (50 total): strand 17, helix 16, turn 6, modified residue 3, region of interest 2, initiator methionine 1, chain 1, cross-link 1, domain 1, coiled-coil region 1, binding site 1

Structure

Experimental structures (PDB)

31 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
1BG2	X-RAY DIFFRACTION	1.8
5LT1	X-RAY DIFFRACTION	1.95
5LT0	X-RAY DIFFRACTION	2
4LNU	X-RAY DIFFRACTION	2.19
9L7E	X-RAY DIFFRACTION	2.4
5LT3	X-RAY DIFFRACTION	2.59
5LT2	X-RAY DIFFRACTION	2.6
1MKJ	X-RAY DIFFRACTION	2.7
9L6K	X-RAY DIFFRACTION	2.8
9L78	X-RAY DIFFRACTION	2.82
5LT4	X-RAY DIFFRACTION	2.88
9GNQ	ELECTRON MICROSCOPY	2.9
7TR2	ELECTRON MICROSCOPY	3
8RHB	ELECTRON MICROSCOPY	3
8RHH	ELECTRON MICROSCOPY	3
7TR1	ELECTRON MICROSCOPY	3.1
4HNA	X-RAY DIFFRACTION	3.19
9L7M	ELECTRON MICROSCOPY	3.48
8RIK	ELECTRON MICROSCOPY	3.6
8RIZ	ELECTRON MICROSCOPY	3.6
6OJQ	ELECTRON MICROSCOPY	3.67
8IXA	ELECTRON MICROSCOPY	4.2
8IXB	ELECTRON MICROSCOPY	4.2
8IXD	ELECTRON MICROSCOPY	4.4
8IXE	ELECTRON MICROSCOPY	4.4
8IXF	ELECTRON MICROSCOPY	4.4
8IXG	ELECTRON MICROSCOPY	4.4
3J8X	ELECTRON MICROSCOPY	5
3J8Y	ELECTRON MICROSCOPY	5
2P4N	ELECTRON MICROSCOPY	9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P33176-F1	79.17	0.30

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 85–92

Post-translational modifications (4): 213, 2, 933, 956

Function

Pathways and Gene Ontology

Reactome pathways

23 pathways

ID	Pathway
R-HSA-2132295	MHC class II antigen presentation
R-HSA-264876	Insulin processing
R-HSA-5625970	RHO GTPases activate KTN1
R-HSA-6811434	COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-9725370	Signaling by ALK fusions and activated point mutants
R-HSA-983189	Kinesins
R-HSA-109582	Hemostasis
R-HSA-1280218	Adaptive Immune System
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-168256	Immune System
R-HSA-194315	Signaling by Rho GTPases
R-HSA-195258	RHO GTPase Effectors
R-HSA-199991	Membrane Trafficking
R-HSA-2980736	Peptide hormone metabolism
R-HSA-392499	Metabolism of proteins
R-HSA-5653656	Vesicle-mediated transport
R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers
R-HSA-6811442	Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-8856688	Golgi-to-ER retrograde transport
R-HSA-9700206	Signaling by ALK in cancer
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3
R-HSA-983231	Factors involved in megakaryocyte development and platelet production

MSigDB gene sets: 384 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, GOBP_SYNAPTIC_VESICLE_LOCALIZATION, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_AXO_DENDRITIC_TRANSPORT, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_VESICLE_LOCALIZATION, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_RESPONSE_TO_PEPTIDE, GOCC_VACUOLAR_MEMBRANE, GOCC_KINESIN_COMPLEX, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION

GO Biological Process (22): microtubule-based movement (GO:0007018), cytoplasm organization (GO:0007028), axon guidance (GO:0007411), positive regulation of synaptic transmission, GABAergic (GO:0032230), lysosome localization (GO:0032418), stress granule disassembly (GO:0035617), natural killer cell mediated cytotoxicity (GO:0042267), regulation of membrane potential (GO:0042391), positive regulation of potassium ion transport (GO:0043268), vesicle transport along microtubule (GO:0047496), mitochondrion transport along microtubule (GO:0047497), synaptic vesicle transport (GO:0048489), centrosome localization (GO:0051642), cellular response to type II interferon (GO:0071346), plus-end-directed vesicle transport along microtubule (GO:0072383), anterograde dendritic transport of neurotransmitter receptor complex (GO:0098971), regulation of modification of synapse structure, modulating synaptic transmission (GO:0098987), anterograde axonal protein transport (GO:0099641), mitocytosis (GO:0160040), positive regulation of protein localization to plasma membrane (GO:1903078), anterograde neuronal dense core vesicle transport (GO:1990048), retrograde neuronal dense core vesicle transport (GO:1990049)

GO Molecular Function (11): microtubule motor activity (GO:0003777), ATP binding (GO:0005524), microtubule binding (GO:0008017), plus-end-directed microtubule motor activity (GO:0008574), ATP hydrolysis activity (GO:0016887), identical protein binding (GO:0042802), protein-containing complex binding (GO:0044877), cadherin binding (GO:0045296), nucleotide binding (GO:0000166), cytoskeletal motor activity (GO:0003774), protein binding (GO:0005515)

GO Cellular Component (22): cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829), kinesin complex (GO:0005871), microtubule (GO:0005874), membrane (GO:0016020), nuclear membrane (GO:0031965), vesicle (GO:0031982), dendrite cytoplasm (GO:0032839), centriolar satellite (GO:0034451), ciliary rootlet (GO:0035253), phagocytic vesicle (GO:0045335), perinuclear region of cytoplasm (GO:0048471), sperm end piece (GO:0097229), postsynaptic cytosol (GO:0099524), cytolytic granule membrane (GO:0101004), axon cytoplasm (GO:1904115), lysosome (GO:0005764), lysosomal membrane (GO:0005765), cytoskeleton (GO:0005856), endocytic vesicle (GO:0030139), neuron projection (GO:0043005)

Reactome top-level categories

Rollup of top-14 pathways:

Category	Pathways
Adaptive Immune System	1
Peptide hormone metabolism	1
RHO GTPase Effectors	1
Golgi-to-ER retrograde transport	1
Signaling by ALK in cancer	1
Factors involved in megakaryocyte development and platelet production	1
Immune System	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Vesicle-mediated transport	1
Metabolism of proteins	1
Disease	1
Membrane Trafficking	1
Intra-Golgi and retrograde Golgi-to-ER traffic	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	7
cytoplasm	3
organelle transport along microtubule	2
ATP-dependent activity	2
binding	2
neuron projection cytoplasm	2
microtubule-based process	1
cellular component organization	1
axonogenesis	1
neuron projection guidance	1
regulation of synaptic transmission, GABAergic	1
positive regulation of synaptic transmission	1
synaptic transmission, GABAergic	1
vacuolar localization	1
protein-RNA complex disassembly	1
organelle disassembly	1
leukocyte mediated cytotoxicity	1
natural killer cell mediated immunity	1
monoatomic ion transmembrane transport	1
regulation of biological quality	1
potassium ion transport	1
regulation of potassium ion transport	1
positive regulation of monoatomic ion transport	1
vesicle cytoskeletal trafficking	1
establishment of mitochondrion localization, microtubule-mediated	1
transport	1
cellular process	1
establishment of vesicle localization	1
synaptic vesicle localization	1
microtubule organizing center localization	1
response to type II interferon	1
cellular response to cytokine stimulus	1
vesicle transport along microtubule	1
plus-end-directed organelle transport along microtubule	1
receptor localization to synapse	1
anterograde dendritic transport	1
chemical synaptic transmission	1
modulation of chemical synaptic transmission	1
regulation of modification of synaptic structure	1
anterograde axonal transport	1

Protein interactions and networks

STRING

2802 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KIF5B	KLC1	Q07866	990
KIF5B	KLC2	Q9H0B6	982
KIF5B	KLC3	Q6P597	976
KIF5B	RANBP2	P49792	969
KIF5B	SYBU	Q9NX95	964
KIF5B	KLC4	Q9NSK0	907
KIF5B	SYNE4	Q8N205	894
KIF5B	PLEKHM2	Q8IWE5	854
KIF5B	RET	P07949	822
KIF5B	ALK	Q9UM73	822
KIF5B	ARL8B	Q9NVJ2	820
KIF5B	EML4	Q9HC35	807
KIF5B	TRAK1	Q9UPV9	798
KIF5B	RET	P07949	773
KIF5B	BSN	Q9UPA5	772

IntAct

299 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
YWHAQ	WDR62	psi-mi:“MI:0914”(association)	0.830
YWHAH	ABLIM1	psi-mi:“MI:0914”(association)	0.800
HOMER1	TRAF5	psi-mi:“MI:0914”(association)	0.740
KLC1	KIF5B	psi-mi:“MI:0914”(association)	0.730
KIF5B	KLC1	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
KIF5B	KIF5B	psi-mi:“MI:0407”(direct interaction)	0.680
KIF5B	KIF5B	psi-mi:“MI:0915”(physical association)	0.680
FYCO1	KIF5B	psi-mi:“MI:0915”(physical association)	0.640
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
HSF2BP	KIF5B	psi-mi:“MI:0915”(physical association)	0.560
KIF5B	CDR2	psi-mi:“MI:0915”(physical association)	0.560
	KIF5B	psi-mi:“MI:0915”(physical association)	0.560
KIF5B	ZBTB8A	psi-mi:“MI:0915”(physical association)	0.560
KIF5B	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
KIF5B	POU6F2	psi-mi:“MI:0915”(physical association)	0.560
KIF5B	FHL2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (505): KIF5B (Affinity Capture-MS), PRKAR2B (Two-hybrid), VPS52 (Two-hybrid), TAX1BP1 (Two-hybrid), ZBTB8A (Two-hybrid), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS), KIF5B (Affinity Capture-MS)

ESM2 similar proteins: A0JN40, A8BB91, A8BKD1, B1AVY7, B9F2Y7, F1M4A4, F1M5N7, F1QN54, F4K0J3, G5EGS3, O14782, O15066, O35066, O55165, O60333, O75037, O88658, P28741, P33173, P33176, P34540, P35978, P46867, P46871, P46872, P46873, Q10E64, Q12756, Q29DY1, Q2PQA9, Q4R628, Q5JKW1, Q5R4H3, Q5R706, Q60575, Q61768, Q61771, Q6YUL8, Q7Z4S6, Q86Z98

Diamond homologs: A0A068FIK2, A0JN40, A1ZAJ2, A8BB91, A8BKD1, B1AVY7, B7EJ91, B7ZNG0, B9F2Y7, B9GE13, F1M4A4, F1M5N7, F1QN54, F4IIS5, F4J1U4, F4K0J3, G5EGS3, O14343, O14782, O15066, O23826, O35066, O35071, O35787, O43896, O45935, O55165, O60282, O60333, O75037, O88658, O95239, P17210, P21613, P23678, P28738, P28741, P33173, P33174, P33175

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
KTN1	up-regulates	KIF5B	binding
DISC1	“up-regulates activity”	KIF5B	binding
KIF5B	up-regulates	Organelle_transport
KIF5B	“up-regulates activity”	SYBU	relocalization
KIF5B	up-regulates	“Plus-end directed sliding movement”
KIF5B	“up-regulates activity”	JAKMIP1	relocalization
KIF5B	“up-regulates activity”	GABBR1	relocalization

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 165 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	49.4×	1e-08
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	43.5×	2e-08
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	43.5×	2e-08
Activation of BH3-only proteins	7	32.2×	1e-07
RHO GTPases activate PKNs	7	20.6×	2e-06
Intrinsic Pathway for Apoptosis	7	19.0×	3e-06
FOXO-mediated transcription	6	18.7×	2e-05
Apoptosis	10	15.6×	7e-08

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	7	17.9×	1e-04
negative regulation of innate immune response	5	17.9×	4e-03
intracellular protein localization	9	6.6×	4e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — HNSC.

Clinical variants and AI predictions

ClinVar

135 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	3
Uncertain significance	98
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
1691098	NM_004521.3(KIF5B):c.1493T>C (p.Leu498Pro)	Pathogenic
563765	GRCh37/hg19 10p11.22(chr10:31425682-32599180)x1	Pathogenic
242891	NM_004521.3(KIF5B):c.2252A>G (p.His751Arg)	Likely pathogenic
3370124	NM_004521.3(KIF5B):c.833G>A (p.Arg278Gln)	Likely pathogenic
4820584	NM_004521.3(KIF5B):c.584C>A (p.Thr195Lys)	Likely pathogenic

SpliceAI

2519 predictions. Top by Δscore:

Variant	Effect	Δscore
10:32015506:AAC:A	donor_loss	1.0000
10:32015507:ACC:A	donor_loss	1.0000
10:32015508:C:CA	donor_loss	1.0000
10:32015532:CA:C	donor_gain	1.0000
10:32015544:T:TA	donor_gain	1.0000
10:32015655:TTTAG:T	acceptor_gain	1.0000
10:32015656:TTAG:T	acceptor_gain	1.0000
10:32015657:TAG:T	acceptor_gain	1.0000
10:32015658:AG:A	acceptor_gain	1.0000
10:32015658:AGC:A	acceptor_loss	1.0000
10:32015659:GC:G	acceptor_loss	1.0000
10:32015660:C:CC	acceptor_gain	1.0000
10:32015663:A:AC	acceptor_gain	1.0000
10:32015665:A:AC	acceptor_gain	1.0000
10:32015665:A:C	acceptor_gain	1.0000
10:32017139:TAAC:T	donor_loss	1.0000
10:32017141:A:AC	donor_gain	1.0000
10:32017141:ACCA:A	donor_loss	1.0000
10:32017142:C:CC	donor_gain	1.0000
10:32017142:CCAAT:C	donor_gain	1.0000
10:32017146:T:C	donor_gain	1.0000
10:32017193:T:TA	donor_gain	1.0000
10:32017211:T:TA	donor_gain	1.0000
10:32017355:ACCAA:A	acceptor_gain	1.0000
10:32017356:CCAA:C	acceptor_gain	1.0000
10:32017356:CCAAC:C	acceptor_gain	1.0000
10:32017357:CAAC:C	acceptor_gain	1.0000
10:32017358:AA:A	acceptor_gain	1.0000
10:32017360:C:CC	acceptor_gain	1.0000
10:32017365:C:CT	acceptor_gain	1.0000

AlphaMissense

6419 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:32017199:A:G	I902T	1.000
10:32017199:A:T	I902K	1.000
10:32017202:C:G	R901P	1.000
10:32017254:C:G	A884P	1.000
10:32017262:A:G	L881P	1.000
10:32017266:C:G	A880P	1.000
10:32017293:C:G	A871P	1.000
10:32017304:A:G	L867P	1.000
10:32017325:A:G	L860P	1.000
10:32017335:G:T	R857S	1.000
10:32017337:A:G	L856P	1.000
10:32017337:A:T	L856H	1.000
10:32017344:C:G	A854P	1.000
10:32017345:A:C	N853K	1.000
10:32017345:A:T	N853K	1.000
10:32017347:T:C	N853D	1.000
10:32017349:T:A	D852V	1.000
10:32017350:C:G	D852H	1.000
10:32017352:C:G	R851P	1.000
10:32017357:C:A	L849F	1.000
10:32017357:C:G	L849F	1.000
10:32017358:A:C	L849W	1.000
10:32017358:A:G	L849S	1.000
10:32018055:T:A	K847N	1.000
10:32018055:T:G	K847N	1.000
10:32018057:T:C	K847E	1.000
10:32018060:G:C	H846D	1.000
10:32018068:G:A	T843I	1.000
10:32018071:A:C	L842R	1.000
10:32018071:A:G	L842P	1.000

dbSNP variants (sampled 300 via entrez): RS1000078993 (10:32027467 G>C), RS1000188233 (10:32050870 C>T), RS1000246887 (10:32018900 T>G), RS1000256272 (10:32056682 T>C), RS1000288354 (10:32012987 C>T), RS1000328453 (10:32034203 A>AG), RS1000361603 (10:32041991 C>A), RS1000439489 (10:32019162 C>T), RS1000470413 (10:32049171 T>A,C), RS1000501651 (10:32015337 T>C), RS1000515008 (10:32032778 G>C), RS1000532382 (10:32052607 A>G), RS1000569136 (10:32048755 T>C), RS1000677310 (10:32055235 G>C,T), RS1000751318 (10:32056505 T>C,G)

Disease associations

OMIM: gene MIM:602809 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
skeletal dysplasia	Strong	Autosomal dominant
osteogenesis imperfecta	Strong	Autosomal dominant

Mondo (8): intellectual disability (MONDO:0001071), attention deficit-hyperactivity disorder (MONDO:0007743), skeletal dysplasia (MONDO:0018230), ophthalmoplegia (MONDO:0003425), dilated cardiomyopathy (MONDO:0005021), hypertrophic cardiomyopathy (MONDO:0005045), skeletal muscle disorder (MONDO:0020120), osteogenesis imperfecta (MONDO:0019019)

Orphanet (5): Primary bone dysplasia (Orphanet:364526), Rare hypertrophic cardiomyopathy (Orphanet:217569), Dilated cardiomyopathy (Orphanet:217604), Skeletal muscle disease (Orphanet:98472), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0001644	Dilated cardiomyopathy
HP:0001639	Hypertrophic cardiomyopathy

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001715_12	Bipolar disorder with mood-incongruent psychosis	5.000000e-06
GCST005025_2	Anti-saccade response	9.000000e-06
GCST005956_37	Waist-to-hip ratio adjusted for BMI	2.000000e-08
GCST005962_50	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	2.000000e-06
GCST007096_63	Pulse pressure	3.000000e-09
GCST007099_45	Systolic blood pressure	7.000000e-06
GCST007638_41	Glycine levels	9.000000e-09
GCST010796_1269	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-09
GCST010796_1270	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0006874	antisaccade response measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure
EFO:0009767	glycine measurement
EFO:0004327	electrocardiography

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D009886	Ophthalmoplegia	C10.292.562.750; C10.597.622.447; C11.590.472; C23.888.592.636.447
D010013	Osteogenesis Imperfecta	C05.116.099.708.685; C16.320.737; C17.300.200.540

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL3430888 (CHIMERIC PROTEIN), CHEMBL5465390 (CHIMERIC PROTEIN), CHEMBL5864 (SINGLE PROTEIN), CHEMBL6195572 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 62,191 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1289601	LENVATINIB	4	8,784
CHEMBL2105717	CABOZANTINIB	4	11,177
CHEMBL24828	VANDETANIB	4	42,230

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

90 potent at pChembl≥5 of 92 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.92	IC50	1.2	nM	CHEMBL5618101
8.82	IC50	1.51	nM	STAUROSPORINE
8.77	IC50	1.7	nM	CHEMBL4644274
8.48	IC50	3.3	nM	CHEMBL4643578
8.41	IC50	3.89	nM	CHEMBL5572034
8.30	IC50	5	nM	CHEMBL5171764
8.27	IC50	5.4	nM	CHEMBL4636056
8.22	IC50	6	nM	CHEMBL4634073
8.20	IC50	6.3	nM	CHEMBL4639022
8.15	IC50	7	nM	CHEMBL169390
8.05	IC50	8.86	nM	CHEMBL4790634
8.00	IC50	10	nM	LENVATINIB
7.96	IC50	11	nM	CHEMBL4858720
7.82	IC50	15	nM	CHEMBL4874648
7.72	IC50	19	nM	CHEMBL4634073
7.70	IC50	20	nM	CHEMBL4857808
7.66	IC50	22	nM	CHEMBL4859681
7.51	IC50	31	nM	CHEMBL4638840
7.43	IC50	37	nM	CHEMBL4640601
7.39	IC50	41	nM	CHEMBL440727
7.36	IC50	44	nM	CHEMBL4877264
7.36	IC50	43.7	nM	CHEMBL5620262
7.28	IC50	53	nM	CHEMBL3774904
7.28	IC50	53	nM	CHEMBL3775169
7.25	IC50	56	nM	CHEMBL4636800
7.16	IC50	70	nM	CHEMBL4642409
7.10	IC50	79	nM	CHEMBL4640989
7.10	IC50	80.2	nM	CHEMBL5799517
7.07	IC50	85	nM	CHEMBL3774489
7.05	IC50	90	nM	CHEMBL4853155
6.92	IC50	120	nM	CHEMBL3775557
6.92	IC50	120	nM	CHEMBL4636995
6.89	IC50	129	nM	CHEMBL5619046
6.72	IC50	190	nM	CABOZANTINIB
6.70	IC50	200	nM	CHEMBL3775934
6.62	IC50	240	nM	CHEMBL4854822
6.58	IC50	260	nM	CHEMBL3774953
6.57	IC50	270	nM	CHEMBL3775511
6.42	IC50	380	nM	CHEMBL127907
6.40	IC50	400	nM	VANDETANIB
6.34	IC50	460	nM	CHEMBL3774951
6.34	IC50	460	nM	CHEMBL3775560
6.31	IC50	490	nM	CHEMBL3775879
6.30	IC50	500	nM	CHEMBL478442
6.24	IC50	570	nM	CHEMBL3775903
6.22	IC50	600	nM	CHEMBL3798883
6.21	IC50	620	nM	CHEMBL3775672
6.21	IC50	610	nM	CHEMBL4636995
6.11	IC50	770	nM	CHEMBL4848347
6.03	IC50	940	nM	CHEMBL235851

PubChem BioAssay actives

88 with measured affinity, of 198 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-[6-[2-(propan-2-ylamino)ethoxy]imidazo[1,2-b]pyridazin-3-yl]ethynyl]benzamide	2130928: Inhibition of human KI5B-RET kinase in presence of [gamma33P]-ATP and 10 uM ATP by radiometric HotSpot assay	ic50	0.0012	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1704869: Inhibition of KIF5B-RET fusion protein (unknown origin) by radiometric assay	ic50	0.0015	uM
3-(3,4-dimethoxyphenyl)-5-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diamine	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0017	uM
methyl 4-[4-[7-amino-5-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-6-phenylpyrazolo[1,5-a]pyrimidin-3-yl]benzoyl]piperazine-1-carboxylate	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0033	uM
N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)-3-pyridinyl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide	1895764: Inhibition of KIF5B-RET (unknown origin) assessed as inhibition of RET autophosphorylation expressed in mouse BaF3 cells	ic50	0.0050	uM
[4-[7-amino-5-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-6-phenylpyrazolo[1,5-a]pyrimidin-3-yl]phenyl]-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]methanone	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0054	uM
methyl N-[4-[7-amino-3-(3,4-dimethoxyphenyl)-5-(1-methylpiperidin-4-yl)oxypyrazolo[1,5-a]pyrimidin-6-yl]phenyl]carbamate	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0060	uM
[4-[7-amino-5-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-6-phenylpyrazolo[1,5-a]pyrimidin-3-yl]phenyl]-(4-methylsulfonylpiperazin-1-yl)methanone	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0063	uM
3-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)phenol	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.0070	uM
4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[(6-pyridin-3-yl-1H-pyrazolo[5,4-d]pyrimidin-4-yl)oxy]benzamide	1704869: Inhibition of KIF5B-RET fusion protein (unknown origin) by radiometric assay	ic50	0.0089	uM
Lenvatinib	1204918: Inhibition of KIF5B/RET (unknown origin) autophoshorylation	ic50	0.0100	uM
3-[4-amino-7-[3-(hydroxymethyl)cyclobutyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.0110	uM
methyl N-[4-[4-amino-5-(3-amino-4-chlorophenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexyl]carbamate	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.0150	uM
methyl N-[4-[4-amino-5-(3-amino-4-chlorophenyl)pyrrolo[2,3-d]pyrimidin-7-yl]-1-bicyclo[2.2.2]octanyl]carbamate	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.0200	uM
methyl N-[4-[4-amino-5-(5-amino-4-chloro-2-fluorophenyl)pyrrolo[2,3-d]pyrimidin-7-yl]-1-bicyclo[2.2.2]octanyl]carbamate	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.0220	uM
3-(3,4-dimethoxyphenyl)-5-N-(1-methylpiperidin-4-yl)-6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diamine	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0310	uM
3-(3,4-dimethoxyphenyl)-5-(1-methylpiperidin-4-yl)oxy-6-phenylpyrazolo[1,5-a]pyrimidin-7-amine	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0370	uM
5-[(6,7-dimethoxyquinazolin-4-yl)amino]-4-fluoro-2-methylphenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.0410	uM
N-[3-(2-cyanopropan-2-yl)-5-(4-methylimidazol-1-yl)phenyl]-2-fluoro-4-methyl-5-[2-[6-(2-morpholin-4-ylethoxy)imidazo[1,2-b]pyridazin-3-yl]ethynyl]benzamide	2130928: Inhibition of human KI5B-RET kinase in presence of [gamma33P]-ATP and 10 uM ATP by radiometric HotSpot assay	ic50	0.0437	uM
1-[4-[3-[4-amino-5-(3-amino-4-chlorophenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl]piperazin-1-yl]ethanone	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.0440	uM
5-[(6,7-dimethoxyquinazolin-4-yl)amino]-2,4-difluorophenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.0530	uM
3-[(6,7-dimethoxyquinazolin-4-yl)amino]-4-fluorophenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.0530	uM
3-(3,4-dimethoxyphenyl)-5-N-[3-(dimethylamino)propyl]-6-phenylpyrazolo[1,5-a]pyrimidine-5,7-diamine	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0560	uM
3-(3,4-dimethoxyphenyl)-5-[3-(dimethylamino)propoxy]-6-phenylpyrazolo[1,5-a]pyrimidin-7-amine	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0700	uM
3-(3,4-dimethoxyphenyl)-6-phenyl-5-piperidin-4-yloxypyrazolo[1,5-a]pyrimidin-7-amine	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.0790	uM
4-chloro-3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.0850	uM
1-[4-[3-[4-amino-5-(4-chloro-3-hydroxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl]piperazin-1-yl]ethanone	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.0900	uM
3-[(6,7-dimethoxyquinazolin-4-yl)amino]-2,4-difluorophenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.1200	uM
3-(3,4-dimethoxyphenyl)-5-(1-methylpiperidin-4-yl)oxy-6-(1,3-thiazol-2-yl)pyrazolo[1,5-a]pyrimidin-7-amine	1648939: Inhibition of KIF5B-RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	ic50	0.1200	uM
4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-[6-(2-morpholin-4-ylethoxy)imidazo[1,2-b]pyridazin-3-yl]ethynyl]benzamide	2130928: Inhibition of human KI5B-RET kinase in presence of [gamma33P]-ATP and 10 uM ATP by radiometric HotSpot assay	ic50	0.1290	uM
Cabozantinib	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.1900	uM
3-[(6,7-dimethoxyquinazolin-4-yl)amino]-5-fluorophenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.2000	uM
1-[4-[3-[4-amino-5-(2-fluoro-5-hydroxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl]piperazin-1-yl]ethanone	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.2400	uM
2-chloro-3-[(6,7-dimethoxyquinazolin-4-yl)amino]-4-fluorophenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.2600	uM
4-chloro-3-[(6,7-dimethoxyquinazolin-4-yl)amino]-2-fluorophenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.2700	uM
3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.3800	uM
Vandetanib	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.4000	uM
2-chloro-3-[(6,7-dimethoxyquinazolin-4-yl)amino]-6-methylphenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.4600	uM
3-[(6,7-dimethoxyquinazolin-4-yl)amino]-4-methylphenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.4600	uM
5-[(6,7-dimethoxyquinazolin-4-yl)amino]-2-fluorophenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.4900	uM
5-[(6,7-dimethoxyquinazolin-4-yl)amino]-2-methylphenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.5000	uM
3-[(6,7-dimethoxyquinazolin-4-yl)amino]-2-fluorophenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.5700	uM
4-fluoro-3-[[6-methoxy-7-[3-[2-(trifluoromethyl)pyrrolidin-1-yl]propoxy]quinazolin-4-yl]amino]-2-methylphenol	1298124: Inhibition of recombinant KIF5B/RET (unknown origin) expressed in IL3 deficient BAF3 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	ic50	0.6000	uM
3-(6,7-dimethoxyquinazolin-4-yl)oxyphenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.6200	uM
1-[4-[3-[4-amino-5-(3-hydroxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl]piperazin-1-yl]ethanone	1774878: Inhibition of KIF5B-RET fusion protein (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	ic50	0.7700	uM
2-chloro-5-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	0.9400	uM
4-fluoro-3-[[6-methoxy-7-(pyridin-3-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol	1298124: Inhibition of recombinant KIF5B/RET (unknown origin) expressed in IL3 deficient BAF3 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	ic50	1.1000	uM
3-[(6,7-dimethoxyquinazolin-4-yl)amino]benzene-1,2-diol	1283959: Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay	ic50	1.1000	uM
4-fluoro-3-[[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]amino]-2-methylphenol	1298124: Inhibition of recombinant KIF5B/RET (unknown origin) expressed in IL3 deficient BAF3 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	ic50	1.2000	uM
4-fluoro-3-[[7-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-6-methoxyquinazolin-4-yl]amino]-2-methylphenol	1298124: Inhibition of recombinant KIF5B/RET (unknown origin) expressed in IL3 deficient BAF3 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	ic50	1.3000	uM

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	3
bisphenol A	increases expression, affects cotreatment	2
perfluorooctane sulfonic acid	decreases expression	2
Nickel	increases expression	2
Smoke	decreases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Cyclosporine	increases expression, increases methylation	2
FR900359	decreases phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
bisphenol S	affects expression	1
jinfukang	decreases expression	1
LDN 193189	increases expression, affects cotreatment	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Resveratrol	increases expression, affects cotreatment	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Furaldehyde	decreases expression, affects cotreatment	1
Ivermectin	decreases expression	1
Phenobarbital	affects expression	1
Phenolsulfonphthalein	affects cotreatment, increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Plant Oils	increases expression	1
Ribonucleotides	affects binding	1
Sodium Chloride	affects cotreatment, decreases expression	1
Tamoxifen	affects expression	1

ChEMBL screening assays

43 unique, capped per target: 37 binding, 6 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3428796	Binding	Inhibition of KIF5B/RET (unknown origin) autophoshorylation	Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. — J Med Chem
CHEMBL6091206	Functional	In vivo PROTAC activity at CRBN/KIF5B-RET-G810C mutant in male BALB/c mouse model implanted with mouse BaF3 cells stably expressing KIF5B-RET-G810C mutant assessed as induction of RET degradation in tumor at 10 mg/kg, ip measured after 3 da	Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations. — J Med Chem

Cellosaurus cell lines

11 cell lines: 6 cancer cell line, 5 factor-dependent cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C5VR	CUTO-22	Cancer cell line	Female
CVCL_C5VS	CUTO-32	Cancer cell line	Male
CVCL_SU83	HAP1 KIF5B (-) 1	Cancer cell line	Male
CVCL_SU84	HAP1 KIF5B (-) 2	Cancer cell line	Male
CVCL_UE86	Ba/F3 KIF5B-RET	Factor-dependent cell line
CVCL_XZ23	Ba/F3 KIF5B-RET-F744I/G810A	Factor-dependent cell line
CVCL_XZ24	Ba/F3 KIF5B-RET-V804E	Factor-dependent cell line
CVCL_XZ25	Ba/F3 KIF5B-RET-V804L	Factor-dependent cell line
CVCL_XZ26	Ba/F3 KIF5B-RET-V804M	Factor-dependent cell line
CVCL_YD30	SNU-2612A	Cancer cell line	Male

Clinical trials (associated diseases)

280 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00131469	PHASE4	COMPLETED	Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
NCT00159419	PHASE4	COMPLETED	Bisphosphonate Therapy for Osteogenesis Imperfecta
NCT01713231	PHASE4	COMPLETED	Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
NCT02303873	PHASE4	COMPLETED	Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
NCT03735537	PHASE4	COMPLETED	Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
NCT04152551	PHASE4	RECRUITING	Effects of Bisphosphonates on OI-Related Hearing Loss
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT00001305	PHASE3	COMPLETED	Growth Hormone Therapy in Osteogenesis Imperfecta
NCT00005901	PHASE3	COMPLETED	Pamidronate to Treat Osteogenesis Imperfecta in Children
NCT00106028	PHASE3	COMPLETED	Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
NCT00982124	PHASE3	COMPLETED	An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
NCT02352753	PHASE3	TERMINATED	Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
NCT03638128	PHASE3	TERMINATED	Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
NCT05768854	PHASE3	ACTIVE_NOT_RECRUITING	Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
NCT05972551	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT06636071	PHASE3	ACTIVE_NOT_RECRUITING	Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
NCT07366086	PHASE3	RECRUITING	Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT00063479	PHASE2	COMPLETED	Bisphosphonate Treatment of Osteogenesis Imperfecta
NCT00131118	PHASE2	COMPLETED	Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
NCT01417091	PHASE2	COMPLETED	Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
NCT01679080	PHASE2	TERMINATED	The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
NCT01799798	PHASE2	COMPLETED	Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab
NCT03208582	PHASE2	COMPLETED	Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?
NCT03216486	PHASE2	WITHDRAWN	An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
NCT05312697	PHASE2	TERMINATED	Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
NCT07062588	PHASE2	RECRUITING	Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07557446	PHASE2	NOT_YET_RECRUITING	A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00705120	PHASE1	COMPLETED	Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
NCT02172885	PHASE1	COMPLETED	Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta
NCT03064074	PHASE1	COMPLETED	Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
NCT04545554	PHASE1	COMPLETED	Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
NCT05231668	PHASE1	TERMINATED	Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)